Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.80 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cystetine Triphosphate SCHEMBL15810768 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL105273 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL315351 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL104629 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL18784962 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| SCHEMBL376516 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL4289439 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| SCHEMBL376515 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL104630 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL21311175 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-8841439-B2 | Nucleotide sugar purification using membranes | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-20120083600-A1 | NUCLEOTIDE SUGAR PURIFICATION USING MEMBRANES | NOVO NORDISK A/S (DK) | 2012-04-05 | — | — | US | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY2 2899/4885P2RY6 1545/4885P2RY4 2901/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY2 2899/4885P2RY6 1545/4885P2RY4 2901/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY2 2899/4885P2RY6 1545/4885P2RY4 2901/4885 |
| US-20120083600-A1 | NUCLEOTIDE SUGAR PURIFICATION USING MEMBRANES | SLC35B2, SLC35A1, GALNT1 | P2RY2 240/4885P2RY6 291/4885P2RY4 267/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY2 2899/4885P2RY6 1545/4885P2RY4 2901/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | P2RY2 1037/4885P2RY6 802/4885P2RY4 518/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY2 2899/4885P2RY6 1545/4885P2RY4 2901/4885 |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | P2RY2 580/4885P2RY6 353/4885P2RY4 382/4885 |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ADA, CDA | P2RY2 1313/4885P2RY6 643/4885P2RY4 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.